Antihypertensive Effectiveness of the Associations of Hydrochlorothiazide and Amiloride and Hydrochlorothiazide and Enalapril
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00394394|
Recruitment Status : Completed
First Posted : November 1, 2006
Last Update Posted : November 1, 2006
The majority of hypertensive patients require antihypertensive associations to control their blood pressure. Most of clinical trials don’t compare different associations using Hydrochlorothiazide 25 mg as the standard initial therapy and compare the associations using doses that are not equivalent.
This randomized trial where patients and investigators are blinded and compares the effectiveness two associations: Hydrochlorothiazide and Amiloride and Hydrochlorothiazide and Enalapril.
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: Amiloride 2,5/d or Enalapril/d 10 mg||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Hydrochlorothiazide and Amiloride vs Hydrochlorothiazide and Enalapril: a Randomized Clinical Trial of Antihypertensive Effectiveness.|
|Study Start Date :||February 2005|
- Mean blood pressure measured with 24-hour ambulatory blood pressure monitoring after 12 weeks of follow-up
- Percentage of patients who needed to double the dose of enalapril or amiloride in forth or eighth week or use propranolol in the eighth week follow-up visiting.
- Fasting blood glucose differences between the baseline and twelve-week follow-up visiting.
- Serum potassium differences between the baseline and twelve-week follow-up visiting.
- Serum total cholesterol, LDL- cholesterol, HDL- cholesterol and triglycerides differences between the baseline and twelve-week follow-up visiting.
- Serum uric acid differences between the baseline and twelve-week follow-up visiting.
- Urine microalbuminuria differences between the baseline and twelve-week follow-up visiting.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00394394
|Hospital de Clínicas de Porto Alegre|
|Porto Alegre, Rio Grande do Sul, Brazil, 90035-903|
|Principal Investigator:||Miguel Gus||Hospital de Clínicas de Porto Alegre|